Lifestyle strategies to preserve muscle and reduce cardiovascular risk in adults with obesity using GLP-1 receptor agonists - Project Summary GLP-1 receptor agonists are now among the most widely prescribed weight loss medications in the United States. While effective for weight reduction, up to 25–40% of weight lost is lean mass, raising concerns about mobility, metabolic health, and long-term weight maintenance. Professional societies, including the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society, recommend integrating nutritional management and resistance training for patients starting GLP-1 therapy. Yet rigorous evidence supporting these recommendations in real-world practice is lacking. To address this evidence gap, we propose a randomized trial enrolling 670 adults with obesity (BMI ≥30 or ≥27 with comorbidity) from different socioeconomic groups who initiate GLP-1 therapy. Participants will be randomized within three weeks of their first dose to (1) a GLP-1 Lifestyle Management Program based on YMCA of Florida’s First Coast’s evidence-based physical activity/resistance training programs or (2) enhanced usual care consisting of monthly health education workshops plus standard physician guidance. The First Coast YMCA GLP-1 Lifestyle Management Program will integrate nutritional and exercise components tailored to patients using GLP-1s. An Enhanced usual care group will serve as an attention-matched control without specific diet or exercise prescriptions. The primary outcome is 6-month change in lean mass, as measured by appendicular lean tissue mass by DXA. Secondary outcomes include changes in atherosclerotic cardiovascular disease (ASCVD) risk, total lean mass, weight loss, diet quality, physical activity, and self-reported quality of life. We hypothesize the First Coast YMCA GLP-1 program will (Aim 1) preserve lean mass, (Aim 2) reduce ASCVD risk by improving metabolic markers, and (Aim 3) enhance quality of life compared to enhanced usual care. This study is innovative by (1) targeting a rapidly growing patient population at risk for lean mass loss, including an emphasis on lower-income populations that are disproportionally impacted by obesity; (2) leveraging a nonprofit scalable platform for diet, exercise, and behavior change; and (3) rigorously evaluating ASCVD risk reduction, an outcome rarely measured in this population. Our multidisciplinary team has extensive experience with large clinical trials, weight loss and exercise interventions, biostatistics, and recruitment of low-income populations. Partnerships with the University of Florida and the Florida Department of Health provide access to a large cohort of new GLP-1 users. By producing high-quality evidence on how to integrate lifestyle interventions with GLP-1 therapy, this project will address a critical implementation gap between professional society recommendations and clinical practice, as well as improve long-term outcomes for adults with obesity.